NORMAN J CLEMENT RPH., DDS, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
Summary
youarewithinthenorms.com podcast
The centers of this Podcast are allegations of misconduct against Dr. Timothy King, an expert witness for the Department of Justice (DOJ) and Drug Enforcement Administration (DEA) in opioid-related cases, accusing him of biased and false testimony.
Further, the text criticizes the DEA’s increasing reliance on AI-driven predictive analytics in opioid investigations, highlighting concerns about algorithmic bias and the potential for perpetuating systemic inequities in healthcare.
CLICK BELOW TO LISTEN TO PODCAST
“Eliminating Bias in Algorithmic Systems Act,”
This AI bias is further examined through the lens of congressional efforts, specifically Rep. Summer Lee’s “Eliminating Bias in Algorithmic Systems Act,” which aims to mitigate the risks of biased algorithms in federal agencies.
Senate version introduced by Sen. Ed Markey (D-MA), underscores her commitment to equity in emerging technologies.
This youarewithinthenorms podcast also discusses the historical context of eugenics and its connection to current practices. Finally, the text raises ethical questions about the use of AI in healthcare and justice, questioning the balance between technological advancement and human judgment.
OR SEND
TO CASH APP:$docnorm
ZELLE 3135103378
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
for now, you are withiN
the norms
Algorithmic Justice and the DEA: An 8-Question FAQ
1. What is the controversy surrounding Dr. Timothy King, MD, and his role as a DEA expert witness?
Dr. Timothy King, nicknamed the “Rat King,” is accused of using his expert witness status to push false narratives and biased interpretations in opioid prescription cases. Critics allege he ignores the subjective nature of pain, perpetuates outdated views on opioid addiction, and relies on questionable scientific methods like equianalgesic tables. His testimony, they argue, may be setting a de facto standard of care that negatively impacts patient well-being.
2. How is the DEA using AI and predictive analytics in its fight against the opioid crisis?
The DEA is integrating artificial intelligence (AI) and predictive analytics into its operations, mirroring strategies from the financial sector. Systems like DARTS, DICE, CMS PLATO, Qlarant AI System, and NBI MEDIC aim to “de-conflict” investigations and identify potential opioid trafficking hotspots by analyzing real-time, de-identified data. This approach, however, raises concerns about sacrificing human discretion and real-world context in favor of data-driven predictions.
3. What concerns exist regarding the DEA’s reliance on AI algorithms?
Critics worry that using AI algorithms like those employed by the DEA to predict opioid sales, similar to models used in financial forecasting, could lead to unintended consequences. These concerns include potential bias in the data used to train the algorithms, the risk of oversimplifying complex issues, and the lack of transparency in how these systems make decisions. Additionally, there’s a fear that focusing heavily on data could lead to a disconnect from the human element of the opioid crisis.
4. What are the potential drawbacks of the DEA’s emphasis on “de-identified data”?
While using de-identified data may offer privacy benefits, it also raises concerns about the potential for bias and lack of context. Critics argue that removing identifying information strips away crucial details that could help understand the nuances of individual cases and the broader opioid crisis. This approach, they say, risks reducing complex human situations to mere data points, potentially leading to misguided interventions and policies.
5. What is the “Eliminating Bias in Algorithmic Systems Act of 2024” and its purpose?
Introduced by Rep. Summer Lee (D-PA) and Sen. Markey (D-MA), this Act seeks to address the risk of bias within AI systems used by federal agencies. The Act mandates these agencies to establish dedicated civil rights offices, staffed with experts in bias, discrimination, and AI technology. Their task would be to evaluate the development process, ensure diverse training data sets, and continuously monitor AI tools for inequities, ultimately aiming to prevent harm caused by algorithmic bias.
6. How can algorithmic bias negatively impact healthcare, specifically in the context of the opioid crisis?
Algorithmic bias can lead to unfair and inaccurate healthcare decisions, particularly impacting marginalized communities. In the context of the opioid crisis, biased algorithms might incorrectly flag certain patients as high-risk for abuse based on factors like race or socioeconomic status, leading to denial of necessary pain management medication. This can exacerbate health disparities and contribute to inadequate treatment for those who legitimately need opioid-based pain relief.
7. What are the ethical considerations surrounding the use of AI in law enforcement and healthcare?
The use of AI in sensitive areas like law enforcement and healthcare raises various ethical questions. Key concerns include potential for bias and discrimination, lack of transparency and accountability in decision-making processes, and the challenge of balancing individual privacy with public safety objectives. It’s crucial to establish clear ethical guidelines and regulations to ensure that AI technologies are used responsibly and fairly in these fields.
8. What steps can be taken to mitigate the risks of AI bias in healthcare and ensure equitable treatment for all patients?
To combat AI bias in healthcare, we need multifaceted solutions. These include:
- Diverse training data: Algorithms should be trained on data that accurately reflects the diversity of the population, avoiding overrepresentation of any particular group.
- Transparency and explainability: The decision-making processes of AI systems need to be transparent and understandable, allowing for scrutiny and identification of potential bias.
- Continuous monitoring and auditing: Regular assessments are needed to identify and address any emerging bias in AI systems over time.
- Human oversight: AI should not replace human judgment entirely. Medical professionals should be able to review and override algorithmic decisions when necessary, ensuring personalized patient care.
- Community engagement: Involving communities affected by these technologies in the development and implementation process is crucial to ensure their needs and concerns are addressed.
